Brief: Cereno Reports Favorable Safety, Tolerability Of CS1 Treatment In PAH
31/03/2026 06:39
March 31 (Reuters) - Cereno Scientific AB CRNOSb.ST: REPORTS FAVORABLE SAFETY AND TOLERABILITY AFTER 12 MONTHS OF CS1 TREATMENT IN PAH FROM THE EXPANDED ACCESS PROGRAM CS1 WELL TOLERATED OVER 12 MONTHS WITH NO UNEXPECTED SAFETY CONCERNS OR DRUG-RELATED DISCONTINUATIONS FURTHER ANALYSES FROM EAP INCLUDING IMAGING SUB-STUDY TO BE COMMUNICATED DURING Q2 2026 Source text: ID:nWkr9SjV4 Further company coverage: [CRNOSb.ST] (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Cereno Scientific AB
See all newsBrief: Cereno Scientific Expects Up To 15 Activated Sites By 2026 In Epimode Trial
Brief: Cereno Scientific Reports Positive Results From Study
Brief: Cereno Scientific Q2 Net Sales Sek 0
Sweden's Cereno Scientific Q2 net loss widens, hurt by clinical development costs
Brief: Cereno Scientific Q2 Loss After Financial Items SEK 30.5 Mln